The invention is generally related to an Actinium-225 generator in which neutrons are incident on a first material to generate high energy protons, and the generated protons are then incident on a second material comprising radium-226 to produce Actinium-225.
Recent studies have shown that mortality in men due to prostate cancer is above 358,000 worldwide, and is ranked as the second most frequent cancer after lung cancer [1]-[3]. Metastatic castration-resistant prostate cancer (mCRPC) is an advanced prostate cancer [4], [5], for which clinicians use prostate-specific membrane antigen (PSMA) as a metastatic prostate cancer indicator [6]. This advanced stage of prostate cancer can be considered as a non-curable disease depending on the PSMA level. Recent studies and clinical reports show that molecular radiotherapy using radionuclides such as Lu-177, Bi-213, and Ac-225 [7], [8] can increase the survival rate of patients [7], [9]-[12]. This involves labelling the PSMA with high Alpha or Beta emitter sources for their high Linear Energy Transfer LET and Relative Biological Effect (RBE). Acitnium-225 is the preferred radionuclide as it is an alpha emitter and has both high LET and RBE almost 100 times more than Beta emitters [6].